Which drug works best for shock? major trial to settle debate
NCT ID NCT07562932
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will compare norepinephrine and dopamine as the first drug given to adults with cardiogenic shock, a life-threatening condition where the heart can't pump enough blood. About 512 participants will be randomly assigned to one of the two drugs. The goal is to see which drug reduces the risk of death or worsening shock within the first month, and causes fewer complications like dangerous heart rhythms or need for a heart pump.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
norepinephrine and dopamine (vasopressor drugs)
What this could lead to
If this trial succeeds, it could show which drug is safer and more effective for stabilizing blood pressure and improving survival in cardiogenic shock.
What could go wrong
This is an early-stage comparison trial; results may not apply to all patients. Both drugs have known risks like arrhythmias, and the study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chonnam National University Hospital
Gwangju, 61469, South Korea